Scott Hirsch

Scott Hirsch has over 20 years of experience in healthcare operations, investment management, and financial services, including his most recent role of Interim CEO at Endo, Inc. from August 2024 to July 2025, where he was a board member from April 2024 to August 2025. 

Mr. Hirsch has served as an executive operator and board member for privately held companies within Blackstone, Bain Capital, and Lauder Partner portfolios. From March 2023 to May 2024, Mr. Hirsch served as an operating officer of Quva Pharmaceuticals. Prior to that, Mr. Hirsch was the chief executive officer of Solta Medical, where he led the global company operating in over 50 countries. Prior to Solta, Mr. Hirsch was the President of the Ortho Dermatologics and OraPharma business segments and the Chief Business Officer of Bausch Health/Bausch & Lomb. Prior to Bausch, Mr. Hirsch was a Portfolio Manager at Citadel’s Surveyor Capital fund, overseeing investment and risk management decisions for a healthcare portfolio. 

Mr. Hirsch started his career on Wall Street in the investment banking group of Credit Suisse, where he was recognized by Institutional Investor magazine as a top equity research analyst.

Mr. Hirsch holds an MBA in Healthcare Management and Finance from the Wharton School of University of Pennsylvania and Bachelor of Fine Arts with honors from The Rhode Island School of Design.